Vanda Pharmaceuticals
VNDA
146 hedge funds and large institutions have $207M invested in Vanda Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 44 reducing their positions, and 25 closing their positions.
23% more call options, than puts
Call options by funds: $261K | Put options by funds: $212K
20% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 44
0% more capital invested
Capital invested by funds: $206M → $207M (+$401K)
1.46% less ownership
Funds ownership: 75.45% → 74% (-1.5%)
4% less funds holding
Funds holding: 152 → 146 (-6)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.48M |
| 2 |
BlackRock
New York
|
+$2.44M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.3M |
| 4 |
Millennium Management
New York
|
+$1.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$7.47M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.61M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.23M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.22M |
| 5 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.07M |
VNDA Hedge Fund Activity: Q4 2024 in Review
146 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2024, worth a combined $207M — up 0.19% from $206M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of VNDA and 21 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 53 added.
The largest buyer was Morgan Stanley, adding an estimated $3.48M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $7.47M sold.
- 146 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2024, down from 152 in Q3 2024.
- Funds reported $207M of Vanda Pharmaceuticals stock for Q4 2024, up 0.19% quarter-over-quarter.
- 21 funds opened new Vanda Pharmaceuticals positions in Q4 2024 and 25 closed out, a net change of -4 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $3.48M added.
- The largest Vanda Pharmaceuticals seller in Q4 2024 was Nantahala Capital Management, an estimated $7.47M sold.
Based on aggregated 13F filings for Q4 2024.